A role for antibodies in tumor immunity

International Reviews of Immunology

Volumn 22, Issue 2, 2003, Pages 141-172

  Kennedy, Ronald C ^a   Shearer, Michael H ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antibodies; Immunity; Tumors

Indexed keywords

CANCER ANTIBODY; CANCER VACCINE; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; TUMOR ANTIGEN;

ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; B CELL LYMPHOMA; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELL SURFACE; HUMAN; HYPERSENSITIVITY; LUNG DISEASE; REVIEW; TUMOR CELL; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; VACCINATION;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CLINICAL TRIALS; HUMANS; NEOPLASMS;

EID: 0037700248     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180305222     Document Type: Review

References (71)

1. A.G. Dalgleish, Current problems in the development of specific immunotherapeutic approaches to cancer. J. Clin. Pathol., 54: 675-676, 2001.
2. W.B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893 (classical article) Clin. Orthop., 262: 3-11, 1991.
3. D. Jager, E. Jager, and A. Knuth, Immune response to tumour antigens: Implications for antigen specific immunotherapy of cancer. J. Clin. Pathol., 54: 669-674, 2001.
4. G. Riethmuller, E. Schneider-Gadicke, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, H. Pichlmaier, H. Hirche, R. Pichlmayr, P. Buggischi, J. Witte, and the Germain Cancer Aid 17 Study Group, Randomised, trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
5. A. Mittelman, G.Z.J. Chen, G.Y. Wong, C. Liu, S. Hirai, and S. Ferrone, Human high molecular weight melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenicity in patients with malignant melanoma. Clin. Cancer Res., 1: 705-713, 1995.
6. P.O. Livingston, G.Y. Wong, S. Adluri, Y. Tao, M. Padavan, R. Parente, C. Hanlon, M.J. Calves, F. Helling, and G. Ritter, Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
7. P.O. Livingston, S. Zhang, L. Walberg, G. Ragupathi, F. Helling, and M. Fleischer, Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2-KLH is increased by IgG antibodies. Cancer Immunol. Immunother., 43: 324-330; 1997.
8. G.D. MacLean, M.A. Reddish, R.R. Koganty, and B.M. Longnecker, Antibodies against mucin associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma in patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother., 19: 59-68, 1996.
9. M.L. Disis, S.M. Pupa, J.R. Gralow, R. Dittadi, S. Menard, and M.A. Cheever, High titer HER-2/neu protein specific antibody can be detected in patients with early stage breast cancer. J. Clin. Oncol., 15: 3363-3367, 1997.
10. P.O. Livingston and G. Ragupathi, Carbohydrate vaccines that induce antibodies against cancer: Previous experience and future plans. Cancer Immunol. Immunother., 45: 10-19, 1997.
11. K. Miller, G. Abeles, R. Oratz, A. Zeleniuch-Jacquotte, J. Cui, D.F. Roses, M.N. Harris, and J.C. Bystryn, Improved survival of patients with melanoma with an antibody response to immunization with a polyvalent melanoma vaccine. Cancer, 75: 495-502, 1995.
12. S. Menard, G. Tomasic, P. Casalini, A. Balsari, S. Pilotti, N. Cascinelli, B. Salvadori, M.I. Colnaghi, F. Rilke, Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin. Cancer Res., 3(5): 817-819, 1997.
13. J.A. Coronella, P. Telleman, G.A. Kingsbury, T.D. Truong, S. Hays, R.P. Junghans, Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res., 61(21): 7889-7899, 2001.
14. A. Eisenthal, R. Lafreniere, A.T. Lefor, and S.A. Rosenberg, Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Res., 47: 2771-2776, 1987.
15. I. Hara, Y. Takechi, and A.N. Houghton, Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J. Exp. Med., 182: 1606-1614, 1995.
16. L.W. Law, W.D. Vieira, V.J. Hearing, and D.M. Gersten, Further studies of the therapeutic effects of murine melanoma specific monoclonal antibodies. Biochim. Biophys. Acta., 1226: 105-109, 1994.
17. E. Nagy, I. Berezi, and AH. Sehon, Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol. Immunother., 34: 63-69, 1991.
18. D. Illiopoulos, C. Ernst, Z. Steplewski, J.A. Jambrosic, U. Rodeck, M. Herlyn, W.H. Clark, Jr., H. Koprowski, and D. Herlyn, Inhibition of metastases of human melanoma xenograft by monoclonal antibody to GD2/GD3 gangliosides. J. Natl. Cancer Inst., 6: 440-444, 1989.
19. I. Mujoo, T.J. Kipps, H.M. Yang, D.A. Cheresh, U. Wargalla, D.J. Sander, and R.A. Reisfeld, Functional properties and effect of growth on suppression of human neuroblastoma tumors by isotype switch variants of monoclonal anti-ganglioside GD2 antibody 14.18. Cancer Res., 49: 2857-2861, 1989.
20. H. Zhang, S. Zhang, V.-K.V. Cheung, G. Ragupathi, and P.O. Livingston, Antibodies against GD ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res., 58: 2844-2849, 1998.
21. K.R. Schultz, J.P. Knarnet, R.S. Gieni, K.T. Hayglass, and P.D PD. Greenberg, The role of B cells for in vivo T cell responses to Friend virus induced leukemia. Science, 249: 921-923, 1990.
22. Z. Qin and T. Blankenstein, Tumor growth inhibition mediated by lymphotoxin: Evidence of B lymphocyte involvement in the anti-tumor response. Cancer Res., 55: 4747-4751, 1995.
23. C. Naftzger, Y.L Takechi, H. Kohda, I. Hara, S. Vajayasaradi, and A. Houghton, Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA, 93: 14809-14818, 1996.
24. P.O. Livingston, G. Ritter, and M.J. Calves, Antibody responses after immunization with gangliosides, GM1, GM2, GM3, GD2, and GD3 in the mouse. Cancer Immunol. Immunother., 29: 179-184, 1989.
25. S. Zhang, F. Helling, K.O. Lloyd, and P.O. Livingston, Increased tumor cell reactivity and complement dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol. Immunother, 40: 88-94, 1995.
26. S. Zhang, L.A. Graeber, F. Helling, G. Ragupathi, S. Adluri, K.O. Lloyd, and P.O. Livingston, Augmenting the immunogenicity with a synthetic MUC1 peptide vaccines in mice. Cancer Res., 56: 3315-3319, 1996.
27. Z. Qin, G. Richter, T. Schuler, S. Ibe, X. Cao, and T. Blankenstein, B cell inhibit the induction of T cell dependent tumor immunity. Nature Med., 4: 627-630, 1998.
28. A.M. Watts, R.K. Bright, and R.C. Kennedy, 1999. Antibody-based mechanisms of tumor immunity. In The Antibodies, Vol. 5. J.D. Capra and M. Zannetti, eds., Harwood Academic Publishers pp. 31-62.
29. B.H. Sweet, and M.R. Hilleman, The vacuolating virus SV40. Proc. Soc. Exp. Biol. Med., 105: 420-427, 1960.
30. J.S. Butel, Simian virus 40. In Encyclopedia of Virology, Vol. 3. R.G. Webster and A. Granoff, eds. pp. 1322-1329, 1999.
31. C.A. Holmberg, D.H. Gribble, K.K. Takemoto, P.M. Howley, C. Espana, and B.I. Osburn, Isolation of simian virus 40 from rhesus monkeys (Macaca mulatta) with spontaneous progressive multifocal leukoencephalopathy. J. Infect. Dis., 136: 593-596, 1977.
32. J.P. Hurley, P.O. Ilyinskii, C.J. Horvath, and M.A. Simon, A malignant astrocytoma containing SV40 DNA in a macaque infected with simian immunodeficiency virus. J. Med. Primatol., 26: 172-180, 1997.
33. J.S. Butel and J.A. Lednicky, Cell and molecular biology of simian virus 40: Implications for human infections and disease. J. Natl. Cancer Inst., 91: 119-134, 1999.
34. M.J. Imperiale, H.I. Pass, and M.G. Sanda, Prospects for an SV40 vaccine. Semin. Cancer Biol., 11: 81-85, 2001.
35. A.M. Lewis and J. Cook, A new role for DNA viruses early proteins in carcinogenesis. Science, 227: 15-20, 1985.
36. R.K. Bright, E.T. Kimchi, M.H. Shearer, R.C. Kennedy, and H.I. Pass, SV40 Tag-specific cytotoxic T lymphocytes generated from the peripheral blood of malignant pleural mesothelioma in patients. Cancer Immunol. Immunother., 50: 682-690, 2002.
37. B.E. Eddy, G.S. Borman, W.H. Berkeley, and R.D. Young, Tumors induced in hamsters by injection of rhesus monkey kidney extracts. Proc. Soc. Exp. Biol. Med., 107: 191-197, 1961.
38. R.L. Kirschstein and P. Gerber, Ependymomas produced after intracerebral inoculation of SV40 into newborn hamsters. Nature, 195: 299-300, 1962.
39. M. Carbone, A.M. Lewis, B.J. Matthews, A.S. Levine, and K. Dixon, Characterization of hamster tumors induced by SV40 small tag deletion mutants as true histiocytic lymphomas. Cancer Res., 49: 1565-1571, 1989.
40. C. Cicala, F. Pompetti, and M. Carbone, SV40 induces mesotheliomas in hamsters. Am. J. Pathol., 142: 1524-1533, 1993.
41. D. Ewald, M. Li., S. Efrat, G. Auer, R.J. Wall, P.A. Furth, and L. Henninghausen, Time sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science, 273: 1384-1386, 1996.
42. A.R. Sepulveda, M.J. Finegold, B. Smith, B.L. Slagle, J.L. DeMayo, R.F. Shen, and J.S. Butel, Development of a transgenic mouse system for analysis of stages in liver carcinogenesis using tissue specific expression of SV40 large tumor antigen control led by regulatory elements of the human alpha-1antitrypsin gene. Cancer Res., 49: 6108-6117, 1989.
43. C. Perez-Stable, N.H. Altman, P.P. Mehta, L.J. Deftos, and B. Ross, Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res., 57: 900-906, 1997.
44. S. Kit, T. Kurimura, and D.R. Dubbs, Transplantable mouse tumor line induced by injection of SV40 transformed mouse kidney cells. Int. J. Cancer, 4: 384-392, 1969.
45. A.M. Watts, M.H. Shearer, H.I. Pass, and R.C. Kennedy, Development of an experimental murine pulmonary metastasis model incorporating a viral encoded tumor specific antigen. J. Virol. Meth., 69: 93-102, 1997.
46. A.M. Watts and R.C. Kennedy, Quantitation of tumor foci in an experimental murine tumor model using computer assisted video imaging. Anal. Biochem., 256: 217-219, 1998.
47. A.M. Watts, M.H. Shearer, H.I. Pass, and R.C. Kennedy, Comparison of SV40 large T-ag recombinant protein and DNA immunization in the induction of protective immunity from experimental pulmonary metastasis model. Cancer Immunol. Immunother. 47: 343-351, 1999b.
48. B.B. Knowles, M. Koncar, K. Pfizenmaier, D. Solter, D.P. Aden, and G. Trinchieri, Genetic control of the cytotoxic T cell response to SV40 tumor associated specific antigen. J. Immunol., 122: 1798-1806, 1979.
49. S.S. Tevethia, Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. Mol. Biol. Med., 7: 83-96, 1990.
50. J.L. Anderson, R.G. Martin, C. Chang, P.T. Mora, and D.M. Livingston, Nuclear preparations of SV40 transformed cells contain tumor specific transplantion antigen activity. Virology, 76: 420-426, 1977.
51. L.W. Law, K.K. Takemoto, M.J. Rogers, and R.C. Ting, Induction of simian virus 40 transplantation immunity in mice by SV40 transformed cells from various species. J. Natl. Cancer Inst., 59: 1523-1526, 1977.
52. R.C. Kennedy, K. Adler-Storthz, R.D. Henkel, Y. Sanchez, J.L. Melnick, and G.R. Dreesman, Immune response to hepatitis B surface antigen: Enhancement by prior injection of antibodies to the idiotype. Science, 221: 853-855, 1983.
53. R.C. Kennedy, E.-M. Zhou, R.E. Lanford, T.C. Chanh, and C.A. Bona, Possible role of anti-idiotypic antibodies in the induction of tumor immunity. J. Clin. Invest., 80: 1217-1224, 1987.
54. R.L. Mernaugh, M.H. Shearer, R.K. Bright, R.E. Lanford, and R.C. Kennedy, Idiotype network components are involved in murine response to simian virus 40 large tumor antigen. Cancer Immunol. Immunother., 35: 113-118, 1992.
55. R.C. Kennedy, G.R. Dreesman, J.S. Butel, and R.E. Lanford, Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving anti-idiotypic antibodies. J. Exp. Med., 161: 1432-1449, 1985.
56. M.H. Shearer, R.E. Lanford, and R.C. Kennedy, Monoclonal anti-idiotypic antibodies induce antibody responses specific for simian virus 40 large tumor antigen. J. Immunol., 145: 932-939, 1990.
57. M.H. Shearer, R.K. Bright, and R.C. Kennedy, Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype. Cancer Res., 53: 5734-5739, 1993a.
58. R.K. Bright, M.H. Shearer, and R.C. Kennedy, Comparison of the murine humoral immune response to recombinant SV40 large tumor antigen: Epitope specificity and idiotype analyses. Cancer Immunol. Immunother., 37: 31-39, 1993.
59. M.H. Shearer, R.K. Bright, R.E. Lanford, and R.C. Kennedy, Immunization of mice with baculovirus derived recombinant SV40 large tumor antigen induces protective tumor immunity to a lethal challenge with SV40-transformed cells. Clin. Exp. Immunol., 91: 266-271, 1993b.
60. M.H. Shearer, R.K. Bright, and R.C. Kennedy, Molecular characterization of immunoglobulin variable regions from murine monoclonal antibodies specific for simian virus 40 large tumor antigen. Scand. J. Immunol., 40: 415-422, 1994.
61. R.K. Bright, M.H. Shearer, and R.C. Kennedy, SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice. Mol. Immunol., 31: 1077-1087, 1994a.
62. R.K. Bright, M.H. Shearer, and R.C. Kennedy, Immunization of BALB/c mice with recombinant SV40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity (ADCC) against SV40 transformed cells: An antibody based mechanism for tumor immunity. J. Immunol., 153: 2064-2071, 1994b.
63. R.K. Bright, M.H. Shearer, and R.C. Kennedy, Examination of lymphokines induced in mice following immunization with recombinant simian virus 40 large tumor antigen. Cancer Immunol. Immunother., 40: 206-213, 1995a.
64. P.J. Southern, and P. Berg, Tranformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. J. Mol. Appl. Genet., 1: 327-341, 1982.
65. R.K. Bright, M.H. Shearer, and R.C. Kennedy, Nucleic acid vaccination against viral induced tumors. Ann. NY Acad. Sci., 772: 241-251, 1995b.
66. D.B. Weiner, and R.C. Kennedy, DNA vaccines. Scientific American, 281: 50-57, 1999.
67. R.K. Bright, B. Beames, M.H. Shearer, and R.C. Kennedy, Protection against a lethal tumor challenge with simian virus 40 transformed cells by the direct injection of DNA encoding SV40 large tumor antigen. Cancer Res., 56: 1126-1130, 1996.
68. A.M. Watts, R.K. Bright, and R.C. Kennedy, DNA cancer vaccination strategies target SV40 large tumour antigen in a murine experimental metastasis model. Dev. Biol. Stand., 104: 143-147, 2000.
69. Y.C. Xie, C. Hwang, W. Overwijk, Z. Zeng, M.H. Eng, J.J. Mule, M.J. Imperiale, N.P. Restifo, and M.G. Sanda, Induction of tumor antigen specific immunity in vivo by a novel vaccinia vector encoding a safety modified simian virus 40 T antigen. J. Natl. Cancer Inst., 91: 169-175, 1999.
70. O. Utermohlen, C. Schulze-Garg, G. Warnecke, R. Gugle, J. Lohler, and W. Deppert, Simian virus 40 large T antigen specific rejection of mKSA tumor cells in BALB/c mice is critically dependent of both strictly tumor associated, tumor specific CD8 + cytotoxic T lymphocytes and CD4 + T helper cells. J. Virol., 75:10593-10602, 2001.
71. J. Zerrahn, G. Utermohlen, G. Warnecke, W. Deppert, and F. Lehmann-Grube, Protective immunity in BALB/c mice against simian virus 40 induced mKSA tumor resulting from injection of recombinant large antigen. Requirement of CD8 + T lymphocytes. J. Immunol., 156: 3919-3924, 1996.